Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report
Reexamination of tumor tissue samples to identify target mutations is necessary for backline treatment of cholangiocarcinoma. T-DXd is effective in the treatment of HER2 amplification cholangiocarcinoma and is relatively well tolerated after multiple lines of therapy. The combination of multi-target tyrosinase inhibitors is a possible strategy for overcoming resistance in the future.
Authors
- Zhenzhou Yang (ORCID: https://orcid.org/0000-0003-2496-1992)
- Zhi Chen (ORCID: https://orcid.org/0000-0002-3991-8383)
- Xiaohui Bao
- Jin Xiong
- Ni Zhang (ORCID: https://orcid.org/0009-0005-0130-2240)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1097/md.0000000000044094
- Citations
- 1
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01